Sera Prognostics, Inc. (SERA) Financial Analysis & Valuation | Quarter Chart
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregna... more
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercia... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $79.63M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Zhenya Lindgardt |
| IPO Date | 2021-07-15 | CAGR | 14.47% |
| Employees | 72 | Website | seraprognostics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SERA chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $93.34M | P/E | -3.21 | Forward P/E | -3.9 | PEG | — |
| P/S | 1610.69 | P/B | 2.5 | P/CF | -5.37 | P/FCF | -4.01 |
| Sales | $70,000 | Sales 1Y | -35.19% | Sales 3Y | -81.33% | Sales 5Y | 59.09% |
| EPS | $-0.65 | EPS 1Y | -21.18% | EPS 3Y | -48.85% | EPS 5Y | -33% |
| Sales QoQ | 114.29% | EPS QoQ | 5.88% | Sales QoQ Avg | 27.73% | EPS QoQ Avg | 3.03% |
| Gross Margin | -150% | Operating Margin | -53282.86% | Profit Margin | -47475.71% | ROCE | -59.79% |
| ROA | -38% | ROE | -47% | Altman Z Score | -4.51 | Piotroski Score | 3 |
| Current Ratio | 1.98 | Quick Ratio | 1.98 | Cash Ratio | 0.18 | Op. CF Ratio | -0.26 |
| Debt/Equity | 0.05 | Debt/Assets | 0.03 | Lt Debt/Equity | 0.05 | Lt Debt/Cap. | — |
| Intrst Cov. | -5328.29 | Inventory Turnover | — | Asset Turnover | 0 | Receivables Turnover | 7 |
| Enterprise Value | $93.34M | P/E Ratio | -3.21 |
| Forward P/E | -3.9 | PEG Ratio | — |
| P/S Ratio | 1610.69 | P/B Ratio | 2.5 |
| P/CF Ratio | -5.37 | P/FCF Ratio | -4.01 |
| EPS | $-0.65 | EPS Growth 1Y | -21.18% |
| EPS Growth 3Y | -48.85% | EPS Growth 5Y | -33% |
| Revenue Growth 1Y | -35.19% | Gross Margin | -150% |
| Operating Margin | -53282.86% | Profit Margin | -47475.71% |
| ROE | -47% | ROA | -38% |
| ROCE | -59.79% | Current Ratio | 1.98 |
| Quick Ratio | 1.98 | Cash Ratio | 0.18 |
| Debt/Equity | 0.05 | Interest Coverage | -5328.29 |
| Altman Z Score | -4.51 | Piotroski Score | 3 |
Sera Prognostics, Inc. (SERA) valuation & financials
Sera Prognostics, Inc. (SERA) has a market capitalization of $79.63M and trades at a price-to-earnings ratio of -3.2. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Sera Prognostics, Inc.'s revenue grew -35.2% over the last year.
Sera Prognostics, Inc.'s next earnings report is scheduled for November 12, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.14. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)